Letko, Brosseau & Associates’s TScan Therapeutics TCRX Stock Holding History

Letko, Brosseau & Associates’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$94K	Hold	95,875	–	–	﹤0.01%	109
2026 Q1	$96.8K	Hold	95,875	–	–	﹤0.01%	96
2025 Q4	$95.9K	Hold	95,875	–	–	﹤0.01%	97
2025 Q3	$174K	Hold	95,875	–	–	﹤0.01%	92
2025 Q2	$139K	Buy	95,875 +18,775	+24%	+$27.1K	﹤0.01%	88
2025 Q1	$106K	Buy	77,100 +40,900	+113%	+$88.5K	﹤0.01%	84
2024 Q4	$110K	Buy	36,200 +15,500	+75%	+$70.3K	﹤0.01%	96
2024 Q3	$103K	Hold	20,700	–	–	﹤0.01%	98
2024 Q2	$121K	Hold	20,700	–	–	﹤0.01%	100
2024 Q1	$164K	Hold	20,700	–	–	﹤0.01%	97
2023 Q4	$121K	Sell	20,700 -11,700	-36%	-$53.6K	﹤0.01%	91
2023 Q3	$82.9K	Buy	+32,400	New	+$75.6K	﹤0.01%	94

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Letko, Brosseau & Associates's TCRX Position: Q2 2026 in Review

Letko, Brosseau & Associates held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 95,875 shares worth $94K. The position accounts for ﹤0.01% of the portfolio, ranked #109.

Letko, Brosseau & Associates first reported a position in TCRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $174K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Letko, Brosseau & Associates held 95,875 shares of TScan Therapeutics worth $94K as of Q2 2026.
Letko, Brosseau & Associates left its TScan Therapeutics share count unchanged in Q2 2026.
TScan Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #109 holding.
Letko, Brosseau & Associates first reported a position in TScan Therapeutics in Q3 2023 and has held it in 12 quarters since.
Letko, Brosseau & Associates's TScan Therapeutics position peaked at $174K in Q3 2025.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.